These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 34586739

  • 1. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Guo S, Qin H, Liu K, Wang H, Bai S, Liu S, Shao Z, Zhang Y, Song B, Xu X, Shen J, Zeng P, Shi X, Chen H, Gao S, Xu J, Pan Y, Xiong L, Li F, Zhang D, Jiao X, Jin G.
    Clin Transl Med; 2021 Sep; 11(9):e520. PubMed ID: 34586739
    [Abstract] [Full Text] [Related]

  • 2. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA, Rashid S, Singh N, Rashid S, Singh V, Gunjan D, Das P, Dash NR, Pandey RM, Chauhan SS, Gupta S, Saraya A.
    Sci Rep; 2021 Feb 02; 11(1):2824. PubMed ID: 33531550
    [Abstract] [Full Text] [Related]

  • 3. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma.
    Liu DSK, Puik JR, Patel BY, Venø MT, Vahabi M, Prado MM, Webber JP, Rees E, Upton FM, Bennett K, Blaker C, Immordino B, Comandatore A, Morelli L, Sivakumar S, Swijnenburg RJ, Besselink MG, Jiao LR, Kazemier G, Giovannetti E, Krell J, Frampton AE.
    J Exp Clin Cancer Res; 2024 Jul 08; 43(1):189. PubMed ID: 38978141
    [Abstract] [Full Text] [Related]

  • 4. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
    Nesteruk K, Levink IJM, de Vries E, Visser IJ, Peppelenbosch MP, Cahen DL, Fuhler GM, Bruno MJ.
    Pancreatology; 2022 Jun 08; 22(5):626-635. PubMed ID: 35613957
    [Abstract] [Full Text] [Related]

  • 5. miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.
    Xu X, Bhandari K, Xu C, Morris K, Ding WQ.
    Int J Mol Sci; 2023 Apr 13; 24(8):. PubMed ID: 37108374
    [Abstract] [Full Text] [Related]

  • 6. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B, Liu X, Gao Y, Li L, Dong Z.
    Br J Biomed Sci; 2016 Oct 13; 73(4):152-157. PubMed ID: 27922430
    [Abstract] [Full Text] [Related]

  • 7. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB, Adai AT, Maghnouj A, Urbanik A, Zöllner H, Liffers ST, Chromik AM, Uhl W, Szafranska-Schwarzbach AE, Tannapfel A, Hahn SA.
    Int J Cancer; 2012 Jul 15; 131(2):E86-95. PubMed ID: 21953293
    [Abstract] [Full Text] [Related]

  • 8. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
    Zeöld A, Sándor GO, Kiss A, Soós AÁ, Tölgyes T, Bursics A, Szűcs Á, Harsányi L, Kittel Á, Gézsi A, Buzás EI, Wiener Z.
    Cell Mol Life Sci; 2021 Mar 15; 78(6):3005-3020. PubMed ID: 33237353
    [Abstract] [Full Text] [Related]

  • 9. Identification of Chronic Pancreatitis Associated microRNAs and Genes for the Diagnosis of Pancreatic Cancer.
    Gong J, Zhang Q, Peng Q, Shi D.
    Am Surg; 2024 Nov 15; 90(11):2797-2807. PubMed ID: 38708574
    [Abstract] [Full Text] [Related]

  • 10. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL, Liu S, Tai MC, Rajapakshe K, Huang Y, Longton G, DeCapite C, Hurd MW, Paris PL, Kirkwood KS, Coarfa C, Maitra A, Brand RE, Killary AM, Sen S.
    Cancer Prev Res (Phila); 2021 Jul 15; 14(7):729-740. PubMed ID: 33893071
    [Abstract] [Full Text] [Related]

  • 11. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.
    Nakamura S, Sadakari Y, Ohtsuka T, Okayama T, Nakashima Y, Gotoh Y, Saeki K, Mori Y, Nakata K, Miyasaka Y, Onishi H, Oda Y, Goggins M, Nakamura M.
    Ann Surg Oncol; 2019 Jul 15; 26(7):2104-2111. PubMed ID: 30820789
    [Abstract] [Full Text] [Related]

  • 12. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
    Vila-Navarro E, Duran-Sanchon S, Vila-Casadesús M, Moreira L, Ginès À, Cuatrecasas M, Lozano JJ, Bujanda L, Castells A, Gironella M.
    Clin Transl Gastroenterol; 2019 Apr 15; 10(4):e00029. PubMed ID: 31009404
    [Abstract] [Full Text] [Related]

  • 13. Dysregulation of miRNAs Targeting the IGF-1R Pathway in Pancreatic Ductal Adenocarcinoma.
    Dobre M, Herlea V, Vlăduţ C, Ciocîrlan M, Balaban VD, Constantinescu G, Diculescu M, Milanesi E.
    Cells; 2021 Jul 22; 10(8):. PubMed ID: 34440625
    [Abstract] [Full Text] [Related]

  • 14. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
    Cote GA, Gore AJ, McElyea SD, Heathers LE, Xu H, Sherman S, Korc M.
    Am J Gastroenterol; 2014 Dec 22; 109(12):1942-52. PubMed ID: 25350767
    [Abstract] [Full Text] [Related]

  • 15. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
    Wang C, Sun Y, Wu H, Yu S, Zhang L, Meng Y, Liu M, Yang H, Liu P, Mao X, Lu Z, Chen J.
    Tumour Biol; 2015 Dec 22; 36(12):9447-56. PubMed ID: 26124009
    [Abstract] [Full Text] [Related]

  • 16. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M, Makino N, Ikeda Y, Matsuda A, Ito M, Kakizaki Y, Saito Y, Ishizawa T, Kobayashi T, Furukawa T, Ueno Y.
    PLoS One; 2016 Dec 22; 11(7):e0158669. PubMed ID: 27380024
    [Abstract] [Full Text] [Related]

  • 17. MicroRNA Signatures for Pancreatic Cancer and Chronic Pancreatitis: Expression Profiling by NGS.
    Singh N, Khan IA, Rashid S, Rashid S, Roy S, Kaushik K, Kumar A, Das P, Lalwani S, Gupta D, Gunjan D, Dash NR, Chauhan SS, Gupta S, Saraya A.
    Pancreas; 2024 Mar 01; 53(3):e260-e267. PubMed ID: 38345909
    [Abstract] [Full Text] [Related]

  • 18. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Han Y, Drobisch P, Krüger A, William D, Grützmann K, Böthig L, Polster H, Seifert L, Seifert AM, Distler M, Pecqueux M, Riediger C, Plodeck V, Nebelung H, Weber GF, Pilarsky C, Kahlert U, Hinz U, Roth S, Hackert T, Weitz J, Wong FC, Kahlert C.
    J Hematol Oncol; 2023 Feb 03; 16(1):7. PubMed ID: 36737824
    [Abstract] [Full Text] [Related]

  • 19. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E.
    Mol Cancer; 2014 May 20; 13():114. PubMed ID: 24884871
    [Abstract] [Full Text] [Related]

  • 20. Serum miR-210-3p can be used to differentiate between patients with pancreatic ductal adenocarcinoma and chronic pancreatitis.
    Guz M, Jeleniewicz W, Cybulski M, Kozicka J, Kurzepa J, Mądro A.
    Biomed Rep; 2021 Jan 20; 14(1):10. PubMed ID: 33235725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.